Insights

Innovative Therapeutics Development Double Bond Pharmaceutical focuses on developing first-in-class therapies for severe diseases such as cancer and autoimmune disorders, offering opportunities to collaborate on cutting-edge drug discovery projects and innovative treatment solutions.

Strategic Clinical Partnerships The company's recent engagement with Cytel Inc for adaptive clinical trial design indicates openness to advanced research methodologies, creating potential for joint ventures in clinical research services and customized trial management.

Distribution Expansion Potential Partnering with Tamro AB for distribution across Scandinavia reveals a platform for suppliers of pharmaceutical products to access new markets through collaborative distribution, storage, and supply chain solutions.

Emerging Market Presence With a focus on unmet medical needs and a growing global patient population, there is significant sales opportunity in providing innovative medicines and related healthcare products that improve patient outcomes in life-threatening conditions.

Technology Enablement Leveraging their tech stack including digital analytics and modern web tools, the company is positioned to adopt digital marketing and data-driven sales strategies, enhancing outreach to healthcare providers and research institutions.

Double Bond Pharmaceutical International AB Tech Stack

Double Bond Pharmaceutical International AB uses 8 technology products and services including WordPress, MySQL, Google Fonts API, and more. Explore Double Bond Pharmaceutical International AB's tech stack below.

  • WordPress
    Content Management System
  • MySQL
    Database
  • Google Fonts API
    Font Scripts
  • TweenMax
    Javascript Frameworks
  • parallax.js
    Javascript Libraries
  • Slider Revolution
    Miscellaneous
  • PHP
    Programming Languages
  • Google Analytics
    Web Analytics

Double Bond Pharmaceutical International AB's Email Address Formats

Double Bond Pharmaceutical International AB uses at least 1 format(s):
Double Bond Pharmaceutical International AB Email FormatsExamplePercentage
First@doublebp.comJohn@doublebp.com
50%
First@doublebp.comJohn@doublebp.com
50%

Frequently Asked Questions

Where is Double Bond Pharmaceutical International AB's headquarters located?

Minus sign iconPlus sign icon
Double Bond Pharmaceutical International AB's main headquarters is located at Virdings allé 32B, Uppsala, Uppsala 75450, SE. The company has employees across 4 continents, including EuropeAfricaNorth America.

What is Double Bond Pharmaceutical International AB's official website and social media links?

Minus sign iconPlus sign icon
Double Bond Pharmaceutical International AB's official website is doublebp.com and has social profiles on LinkedInCrunchbase.

What is Double Bond Pharmaceutical International AB's NAICS code?

Minus sign iconPlus sign icon
Double Bond Pharmaceutical International AB's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Double Bond Pharmaceutical International AB have currently?

Minus sign iconPlus sign icon
As of October 2025, Double Bond Pharmaceutical International AB has approximately 13 employees across 4 continents, including EuropeAfricaNorth America. Key team members include Head Of Clinical Development: C. G. F.Co Founder And Contributing To Finances: M. A.Quality Assurance Manager: E. D.. Explore Double Bond Pharmaceutical International AB's employee directory with LeadIQ.

What industry does Double Bond Pharmaceutical International AB belong to?

Minus sign iconPlus sign icon
Double Bond Pharmaceutical International AB operates in the Pharmaceutical Manufacturing industry.

What technology does Double Bond Pharmaceutical International AB use?

Minus sign iconPlus sign icon
Double Bond Pharmaceutical International AB's tech stack includes WordPressMySQLGoogle Fonts APITweenMaxparallax.jsSlider RevolutionPHPGoogle Analytics.

What is Double Bond Pharmaceutical International AB's email format?

Minus sign iconPlus sign icon
Double Bond Pharmaceutical International AB's email format typically follows the pattern of First@doublebp.com. Find more Double Bond Pharmaceutical International AB email formats with LeadIQ.

When was Double Bond Pharmaceutical International AB founded?

Minus sign iconPlus sign icon
Double Bond Pharmaceutical International AB was founded in 2014.

Double Bond Pharmaceutical International AB

Pharmaceutical ManufacturingSweden11-50 Employees

Double Bond Pharmaceutical is a fast growing pharmaceutical company that develops and commercializes innovative first-in-class approaches for treatment of cancers, infections, autoimmune diseases and other life-threatening disorders. 

The main aim of the company is to provide patients and the market with more efficient and safe products especially in areas where these needs are unmet.

The human population is growing and also the life-span is increasing. Many children born today can be expected to live until they are about 100 years old. By these reasons it can be expected that the need for efficient therapies for treatment of different diseases will steadily increase.

Thus, the aim of the company is to design better medicinal products for patients suffering from diseases such as cancer, inflammation, asthma or diabetes since the primary end-point is the well-being of the patient. Everything counts if it improves the health condition and quality of life for patients afflicted with life-threatening diseases and no medicine or treatment can be viewed as “luxury”. A major problem is that many of the current therapies are not optimal for the patient, implying that the therapy in itself, besides curing the patient, might also cause great suffering in the form of side-effects. Subsequently, we understand that for finding a successful therapy, many ideas about the drug development process which emerged over the past decades have to be reconsidered.

In our strategy to develop superior medicines, we are combining already known efficient approaches with our innovative first-in-class technologies to provide new therapeutic possibilities for treatment of life-threatening diseases. Consequently, we challenge old concepts and evaluate our new ideas in order to prove that the patients will benefit from our invented therapies.

Section iconCompany Overview

Headquarters
Virdings allé 32B, Uppsala, Uppsala 75450, SE
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2014
Employees
11-50

Section iconFunding & Financials

  • $1M

    Double Bond Pharmaceutical International AB's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $1M

    Double Bond Pharmaceutical International AB's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.